Literature DB >> 31107610

Inhibition of intestinal villus cell Na/K-ATPase mediates altered glucose and NaCl absorption in obesity-associated diabetes and hypertension.

Balasubramanian Palaniappan1, Subha Arthur1, Vijaya Lakshmi Sundaram1, Molly Butts1, Shanmuga Sundaram1, Kathiresh Mani1, Soudamani Singh1, Niraj Nepal1, Uma Sundaram1.   

Abstract

During obesity, diabetes and hypertension inevitably coexist and cause innumerable health disparities. In the obesity, diabetes, and hypertension triad (ODHT), deregulation of glucose and NaCl homeostasis, respectively, causes diabetes and hypertension. In the mammalian intestine, glucose is primarily absorbed by Na-glucose cotransport 1 (SGLT1) and coupled NaCl by the dual operation of Na-H exchange 3 (NHE3) and Cl-HCO3 [down-regulated in adenoma (DRA) or putative anion transporter 1 (PAT1)] exchange in the brush border membrane (BBM) of villus cells. The basolateral membrane (BLM) Na/K-ATPase provides the favorable transcellular Na gradient for BBM SGLT1 and NHE3. How these multiple, distinct transport processes may be affected in ODHT is unclear. Here, we show the novel and broad regulation by Na/K-ATPase of glucose and NaCl absorption in ODHT in multiple species (mice, rats, and humans). In vivo, during obesity inhibition of villus-cell BLM, Na/K-ATPase led to compensatory stimulation of BBM SGLT1 and DRA or PAT1, whereas NHE3 was unaffected. Supporting this new cellular adaptive mechanism, direct silencing of BLM Na/K-ATPase in intestinal epithelial cells resulted in selective stimulation of BBM SGLT1 and DRA or PAT1 but not NHE3. These changes will lead to an increase in glucose absorption, maintenance of traditional coupled NaCl absorption, and a de novo increase in NaCl absorption from the novel coupling of stimulated SGLT1 with DRA or PAT1. Thus, these novel observations provide the pathophysiologic basis for the deregulation of glucose and NaCl homeostasis of diabetes and hypertension, respectively, during obesity. These observations may lead to more efficacious treatment for obesity-associated diabetes and hypertension.-Palaniappan, B., Arthur, S., Sundaram, V. L., Butts, M., Sundaram, S., Mani, K., Singh, S., Nepal, N., Sundaram, U. Inhibition of intestinal villus cell Na/K-ATPase mediates altered glucose and NaCl absorption in obesity-associated diabetes and hypertension.

Entities:  

Keywords:  BBM; DRA; NHE3; PAT1; SGLT1

Mesh:

Substances:

Year:  2019        PMID: 31107610      PMCID: PMC6662973          DOI: 10.1096/fj.201802673R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  47 in total

1.  NHE3-dependent cytoplasmic alkalinization is triggered by Na(+)-glucose cotransport in intestinal epithelia.

Authors:  J R Turner; E D Black
Journal:  Am J Physiol Cell Physiol       Date:  2001-11       Impact factor: 4.249

Review 2.  The (Na+ + K+)-activated ATPase. Enzymatic and transport properties.

Authors:  J D Robinson; M S Flashner
Journal:  Biochim Biophys Acta       Date:  1979-08-17

Review 3.  Active sugar transport in health and disease.

Authors:  E M Wright; B A Hirayama; D F Loo
Journal:  J Intern Med       Date:  2007-01       Impact factor: 8.989

Review 4.  Transcriptional regulation of the intestinal luminal Na⁺ and Cl⁻ transporters.

Authors:  Jaleh Malakooti; Seema Saksena; Ravinder K Gill; Pradeep K Dudeja
Journal:  Biochem J       Date:  2011-04-15       Impact factor: 3.857

Review 5.  Regulation of electroneutral NaCl absorption by the small intestine.

Authors:  Akira Kato; Michael F Romero
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

6.  The TALLYHO mouse as a model of human type 2 diabetes.

Authors:  Jung Han Kim; Arnold M Saxton
Journal:  Methods Mol Biol       Date:  2012

7.  Reciprocal regulation of the primary sodium absorptive pathways in rat intestinal epithelial cells.

Authors:  Steven Coon; Ramesh Kekuda; Prosenjit Saha; Uma Sundaram
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-09       Impact factor: 4.249

8.  Renal and intestinal transport defects in Slc26a6-null mice.

Authors:  Zhaohui Wang; Tong Wang; Snezana Petrovic; Biguang Tuo; Brigitte Riederer; Sharon Barone; John N Lorenz; Ursula Seidler; Peter S Aronson; Manoocher Soleimani
Journal:  Am J Physiol Cell Physiol       Date:  2004-12-01       Impact factor: 4.249

Review 9.  The genetic basis of obesity-associated type 2 diabetes (diabesity) in polygenic mouse models.

Authors:  Hans-Georg Joost; Annette Schürmann
Journal:  Mamm Genome       Date:  2014-04-22       Impact factor: 2.957

10.  Decreased basal chloride secretion and altered cystic fibrosis transmembrane conductance regulatory protein, Villin, GLUT5 protein expression in jejunum from leptin-deficient mice.

Authors:  Lana Leung; Jonathan Kang; Esa Rayyan; Ashesh Bhakta; Brennan Barrett; David Larsen; Ryan Jelinek; Justin Willey; Scott Cochran; Tom L Broderick; Layla Al-Nakkash
Journal:  Diabetes Metab Syndr Obes       Date:  2014-07-21       Impact factor: 3.168

View more
  3 in total

1.  Moderate Alcohol Consumption Uniquely Regulates Sodium-Dependent Glucose Co-Transport in Rat Intestinal Epithelial Cells In Vitro and In Vivo.

Authors:  Molly Butts; Soudamani Singh; Jennifer Haynes; Subha Arthur; Uma Sundaram
Journal:  J Nutr       Date:  2020-04-01       Impact factor: 4.798

2.  High Glucose Reduces the Paracellular Permeability of the Submandibular Gland Epithelium via the MiR-22-3p/Sp1/Claudin Pathway.

Authors:  Yan Huang; Hui-Min Liu; Qian-Ying Mao; Xin Cong; Yan Zhang; Sang-Woo Lee; Kyungpyo Park; Li-Ling Wu; Ruo-Lan Xiang; Guang-Yan Yu
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

3.  Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of "SGLT1 bridge" as an indication for "surgical diabetes".

Authors:  Hengliang Zhu; Huajie Cai; Xiaokun Wang; Tao Chen; Chaohui Zhen; Zhenzhan Zhang; Xiaojiao Ruan; Guoxin Li
Journal:  Ann Transl Med       Date:  2022-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.